SrdanVerstovsekMD

Oncology • Houston, TX

Hematologic Oncology

Physician

Join to view full profile

Are you Dr. Verstovsek?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 46 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Summary

Dr. Srdan Verstovsek, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
University at BuffaloResidency, Internal Medicine, 1995 - 1998
University of Zagreb Faculty of MedicineClass of 1992

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1999 - 2024
OK State Medical License 2020 - 2021
IA State Medical License 1997 - 2000

Clinical Trials

Cilengitide in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2004 Jul 01
Terminated
Phase 2
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2004 Oct 01
Terminated
Phase 2
Lenalidomide for Patients With Myelofibrosis (MF) Start of enrollment: 2006 Jul 07
Completed
Phase 2
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Start of enrollment: 2007 Apr 01
Completed
Phase 2
Pegasys® in Patients With Myeloproliferative Diseases Start of enrollment: 2005 Apr 07
Completed
Phase 2
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Start of enrollment: 2004 Jul 01
Completed
Phase 2
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Start of enrollment: 2007 Jun 01
Completed
Phase 1, Phase 2
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases Start of enrollment: 2009 May 01
Completed
Phase 1
Obatoclax for Systemic Mastocytosis Start of enrollment: 2009 Jun 01
Terminated
Phase 2
Pomalidomide for Myelofibrosis Patients Start of enrollment: 2009 Jul 22
Completed
Phase 2
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Start of enrollment: 2009 Aug 01
Completed
Phase 3
A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adult Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Start of enrollment: 2011 Feb 01
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Start of enrollment: 2010 Oct 27
Completed
Phase 3
Phase l/II Study of Ruxolitinib for Acute Leukemia Start of enrollment: 2010 Dec 01
Terminated
Phase 1, Phase 2
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients Start of enrollment: 2011 Mar 01
Completed
Phase 2
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis Start of enrollment: 2011 Sep 22
Completed
Phase 2
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
Completed
Phase 1, Phase 2
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia Start of enrollment: 2013 Feb 21
Completed
Phase 2
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis Start of enrollment: 2013 Oct 01
Completed
Phase 2
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Start of enrollment: 2014 May 01
Completed
Phase 2
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Start of enrollment: 2016 Sep 29
Completed
Phase 2
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) Start of enrollment: 2020 Feb 07
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Ruben Mesa, Jean-Jacques Kiladjian, Claire N Harrison, Stephen T Oh, Alessandro M Vannucchi, Sarah A Buckley, Adam R Craig, Karisse Roman-Torres, John O Mascarenhas, S...> ;Haematologica. 2024 Apr 1
1 citations
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Hudgens, S., Verstovsek, S., Floden, L., Harrison, C., Palmer, J., Gupta, V., McLornan, D., McMullin, M., Kiladjian, J., Foltz, L., Platzbecker, U., Fox, M., Mead, A.,...> ;Value in Health. 2024 Feb 2
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh, S., Verstovsek, S., Gupta, V., Platzbecker, U., Devos, T., Kiladjian, J., McLornan, D., Perkins, A., Fox, M., McMullin, M., Mead, A., Egyed, M., Mayer, J., Sacha, ...> ;Ejhaem. 2024 Feb 1
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase...
Verstovsek, S., Talpaz, M., Wadleigh, M., Isidori, A., Te Boekhorst, P., Savona, M., Bose, P., Pozdnyakova, O., Mesa, R., El-Galaly, T., O'Sullivan, J., Gamel, K., Hig...> ;Haematologica. 2024 Jan 25
Interferons in the treatment of myeloproliferative neoplasms.
Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M Palmer, Aaron T Gerds, Lucia Masarova, Andrew T Kuykendall, Raajit K R...> ;Therapeutic Advances in Hematology. 2024 Jan 1
1 citations
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
Jean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illé...> ;Hemasphere. 2023 Nov 1
2 citations
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Ruben A Mesa, Claire Harrison, Jeanne M Palmer, Vikas Gupta, Donal P McLornan, Mary Frances McMullin, Jean-Jacques Kiladjian, Lynda Foltz, Uwe Platzbecker, Maria Laura...> ;Hemasphere. 2023 Nov 1
Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.
Ivan Krecak, Srdan Verstovsek, Marko Lucijanic> ;Clinical Advances in Hematology & Oncology. 2023 Oct 1
4 citations
Clinical development and management of adverse events associated with FGFR inhibitors.
Vivek Subbiah, Srdan Verstovsek> ;Cell Reports. Medicine. 2023 Oct 17
2 citations
Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
Ivan Krecak, Srdan Verstovsek, Marko Lucijanic> ;Annals of Hematology. 2023 Sep 4
24 citations
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Stephen T Oh, Ruben A Mesa, Claire N Harrison, Prithviraj Bose, Aaron T Gerds, Vikas Gupta, Bart L Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah ...> ;Blood Advances. 2023 Oct 10
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
Vikas Gupta, John Mascarenhas, Marina Kremyanskaya, Raajit K Rampal, Moshe Talpaz, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Srdan Verstovsek, Gozde Colak, Debar...> ;Blood Advances. 2023 Sep 26
2 citations
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an interna...
Aaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mi...> ;The Lancet. Haematology. 2023 Sep 1
2 citations
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Srdan Verstovsek, Ruben A Mesa, Robert A Livingston, Wilson Hu, John Mascarenhas> ;Journal of Hematology & Oncology. 2023 Jul 27
7 citations
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.
Srdan Verstovsek, Ivan Krečak, Florian H Heidel, Valerio De Stefano, Kenneth Bryan, Mike W Zuurman, Michael Zaiac, Mara Morelli, Aoife Smyth, Santiago Redondo, Erwan B...> ;Biomedicines. 2023 Jul 7
3 citations
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
Helen T Chifotides, Srdan Verstovsek, Prithviraj Bose> ;Cancers. 2023 Jun 24
1 citations
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Ruben Mesa, Srdan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Christian Recher, Jean-Jacques Kiladjian, Stephen T Oh, Aaron T Gerds, Timothy ...> ;Haematologica. 2024 Feb 1
1 citations
The role of therapy in the outcome of patients with myelofibrosis.
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Naval G Daver, Koji Sasaki, Helen T Chifotides, Lingsha Zhou, Hagop M Kantarjian, Zeev Estrov, Srdan Verstovsek> ;Cancer. 2023 Sep 15
6 citations
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
Srdan Verstovsek, Lynda Foltz, Vikas Gupta, Robert Hasserjian, Taghi Manshouri, John Mascarenhas, Ruben Mesa, Olga Pozdnyakova, Ellen Ritchie, Ivo Veletic, Katia Gamel...> ;Haematologica. 2023 Oct 1
6 citations
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Naveen Pemmaraju, Prithviraj Bose, Raajit Rampal, Aaron T Gerds, Angela Fleischman, Srdan Verstovsek> ;Leukemia & Lymphoma. 2023 Jun 1
2 citations
Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Pankit Vachhani, Srdan Verstovsek, Prithviraj Bose> ;Expert Opinion on Pharmacotherapy. 2023 Jun 1
8 citations
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Srdan Verstovsek, Ruben Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T Oh, Jean-Jacques Kilad...> ;Blood Advances. 2023 Jul 25
4 citations
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Ruben A Mesa, Stacie Hudgens, Lysbeth Floden, Claire N Harrison, Jeanne Palmer, Vikas Gupta, Donal P McLornan, Mary F McMullin, Jean-Jaques Kiladjian, Lynda Foltz, Uwe...> ;Cancer Medicine. 2023 May 1
3 citations
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera.
Ivan Krecak, Marko Skelin, Srdan Verstovsek> ;Expert Review of Hematology. 2023 May 1
Join now to see all

Press Mentions

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK InhibitorDecember 1st, 2022
FDA Approves Pemigatinib to Treat Rare NeoplasmsAugust 30th, 2022
FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 RearrangementAugust 26th, 2022
Join now to see all

Hospital Affiliations

University of Texas M.D. Anderson Cancer CenterHouston, Texas